Search Results for "amyloidosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: HELIOS-B OLE
Standard response letter on vutrisiran and the open-label extension period of the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Standard response letter on vutrisiran and the open-label extension period of the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Vutrisiran: Analysis of Quality of Life and Physical Function Outcomes in HELIOS-A
Standard response letter on the analysis of quality of life, physical function, and nutritional status outcomes with treatment of vutrisiran in the HELIOS-A study.
Standard response letter on the analysis of quality of life, physical function, and nutritional status outcomes with treatment of vutrisiran in the HELIOS-A study.
Vutrisiran: Use in Patients with Renal Impairment
Standard response letter on vutrisiran and use in patients with renal impairment.
Standard response letter on vutrisiran and use in patients with renal impairment.
Symptoms and Disease Burden of ATTR
Title: Symptoms and Disease Burden of ATTR
External description: This slide deck provides an overview of the symptoms and disease burden of ATTR.
Title: Symptoms and Disease Burden of ATTR External description: This slide deck provides an overview of the symptoms and disease burden of ATTR.
Vutrisiran: Concomitant Use with Tafamidis
Standard response letter on vutrisiran and concomitant use with tafamidis.
Standard response letter on vutrisiran and concomitant use with tafamidis.
Vutrisiran: Survival and Mortality
Standard response letter on mortality and survival data from the HELIOS-B study of vutrisiran.
Standard response letter on mortality and survival data from the HELIOS-B study of vutrisiran.
Vutrisiran: Cardiac Biomarkers in HELIOS-B
Standard response letter on exploratory cardiac biomarker analyses in HELIOS-B.
Standard response letter on exploratory cardiac biomarker analyses in HELIOS-B.
